Label Image (Lbl530021562)
These are Sumatriptan Oral Disintegrating Tablets. The directions for use are provided on the package.*
Sumatriptan
Product Images NDC 53002-2592
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sumatriptan (NDC 53002-2592). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Lbl530022592
Lbl530022593
Figure 1. Estimated Probability Of Achieving Initial Headache Response Within 4 Hours Of Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig1)
Figure 2. The Estimated Probability Of Patients Taking A Second Dose Of Sumatriptan Tablets Or Other Medication To Treat Migraine Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Trials 1, 2, And 3a (Sumatriptan Fig2)
Estimated Probability of Remedication or Rescue is provided in the text along with percentages for different categories. The drug strengths are also mentioned, including placebo, 4 25mg, 50mg, and 100mg. The text also mentions the time frame of "Tie o Howrs From bilial Bese".*
Chemical Structure (Sumatriptan Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
